These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

404 related items for PubMed ID: 25503163

  • 1. Feasibility study of supportive care using lafutidine, a histamine H2 receptor antagonist, to prevent gastrointestinal toxicity during chemotherapy for gastric cancer.
    Namikawa T, Munekage E, Maeda H, Kitagawa H, Kobayashi M, Hanazaki K.
    Anticancer Res; 2014 Dec; 34(12):7297-301. PubMed ID: 25503163
    [Abstract] [Full Text] [Related]

  • 2. Effect of Concomitant Lafutidine on Adjuvant S-1 for Head and Neck Cancer: A Comparative Study.
    Yoshino K, Okamoto I, Sato H, Okada T, Tokashiki K, Kondo T, Tsukahara K.
    Anticancer Res; 2021 Dec; 41(12):6279-6285. PubMed ID: 34848484
    [Abstract] [Full Text] [Related]

  • 3. Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil, oteracil potassium) for gastric cancer.
    Kinoshita T, Nashimoto A, Yamamura Y, Okamura T, Sasako M, Sakamoto J, Kojima H, Hiratsuka M, Arai K, Sairenji M, Fukushima N, Kimura H, Nakajima T.
    Gastric Cancer; 2004 Dec; 7(2):104-9. PubMed ID: 15224197
    [Abstract] [Full Text] [Related]

  • 4. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K, ACTS-GC Group.
    N Engl J Med; 2007 Nov 01; 357(18):1810-20. PubMed ID: 17978289
    [Abstract] [Full Text] [Related]

  • 5. Successful downstaging by S-1-based chemotherapy followed by surgical resections for gastric carcinoma with extensive distant lymph node metastasis - report of two cases and a review of cases with surgical resection after downstaging by S-1-based chemotherapy.
    Yoshida I, Sakurai Y, Komori Y, Tonomura S, Masui T, Shoji M, Nakamura Y, Imazu H, Uyama I, Ochiai M.
    Hepatogastroenterology; 2005 Nov 01; 52(63):978-84. PubMed ID: 15966245
    [Abstract] [Full Text] [Related]

  • 6. Lafutidine, a histamine H2 receptor antagonist with mucosal protective properties, attenuates 5-fluorouracil-induced intestinal mucositis in mice through activation of extrinsic primary afferent neurons.
    Sano T, Utsumi D, Amagase K, Matsumoto K, Tominaga M, Higuchi K, Takeuchi T, Kato S.
    J Physiol Pharmacol; 2017 Feb 01; 68(1):79-90. PubMed ID: 28456772
    [Abstract] [Full Text] [Related]

  • 7. Reduction in gastrointestinal toxicity by gastric secretion inhibitors during S-1 monotherapy for patients with gastric cancer.
    Chisaki Y, Noda S, Hira D, Morita SY, Yano Y, Terada T.
    Biol Pharm Bull; 2014 Feb 01; 37(7):1158-61. PubMed ID: 24989007
    [Abstract] [Full Text] [Related]

  • 8. Effects of a novel histamine H2-receptor antagonist, lafutidine, on the mucus barrier of human gastric mucosa.
    Ichikawa T, Ota H, Sugiyama A, Maruta F, Ikezawa T, Hotta K, Ishihara K.
    J Gastroenterol Hepatol; 2007 Nov 01; 22(11):1800-5. PubMed ID: 17914953
    [Abstract] [Full Text] [Related]

  • 9. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.
    Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, Nasu J, Ohtsu A, Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group.
    Lancet Oncol; 2009 Nov 01; 10(11):1063-9. PubMed ID: 19818685
    [Abstract] [Full Text] [Related]

  • 10. [Three cases of stomatitis caused by chemotherapy for gastrointestinal cancer that responded well to lafutidine].
    Uchida K, Hayashi K, Kuramochi H, Nakajima G, Yamamoto M.
    Gan To Kagaku Ryoho; 2008 Aug 01; 35(8):1435-8. PubMed ID: 18701867
    [Abstract] [Full Text] [Related]

  • 11. Safety and feasibility of adjuvant chemotherapy with S-1 for Korean patients with curatively resected advanced gastric cancer.
    Jeong JH, Ryu MH, Ryoo BY, Lee SS, Park I, Lee SH, Kim KC, Yook JH, Oh ST, Kim BS, Kang YK.
    Cancer Chemother Pharmacol; 2012 Oct 01; 70(4):523-9. PubMed ID: 22864947
    [Abstract] [Full Text] [Related]

  • 12. Phase II feasibility study of adjuvant S-1 plus docetaxel for stage III gastric cancer patients after curative D2 gastrectomy.
    Tamura S, Fujitani K, Kimura Y, Tsuji T, Matsuyama J, Iijima S, Imamura H, Inoue K, Kobayashi K, Kurokawa Y, Furukawa H, Osaka Gastrointestinal Cancer Chemotherapy Study Group.
    Oncology; 2011 Oct 01; 80(5-6):296-300. PubMed ID: 21778769
    [Abstract] [Full Text] [Related]

  • 13. Pilot feasibility study of neoadjuvant chemoradiotherapy with S-1 in patients with locally advanced gastric cancer featuring adjacent tissue invasion or JGCA bulky N2 lymph node metastases.
    Inoue T, Yachida S, Usuki H, Kimura T, Hagiike M, Okano K, Suzuki Y.
    Ann Surg Oncol; 2012 Sep 01; 19(9):2937-45. PubMed ID: 22466666
    [Abstract] [Full Text] [Related]

  • 14. Feasibility and efficacy of preoperative chemotherapy with docetaxel, cisplatin and S-1 in gastric cancer patients with para-aortic lymph node metastases.
    Fushida S, Fujimura T, Oyama K, Yagi Y, Kinoshita J, Ohta T.
    Anticancer Drugs; 2009 Sep 01; 20(8):752-6. PubMed ID: 19543076
    [Abstract] [Full Text] [Related]

  • 15. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.
    Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M.
    Lancet Oncol; 2008 Mar 01; 9(3):215-21. PubMed ID: 18282805
    [Abstract] [Full Text] [Related]

  • 16. [A case of paclitaxel-induced peripheral neuropathy successfully treated by H2-blocker, lafutidine].
    Matsumura T, Imamura H, Kishimoto T, Miyazaki Y, Fujii C, Fujino M, Yasui Y, Anami S, Sumita R, Takada N, Fujita Y, Furukawa H.
    Gan To Kagaku Ryoho; 2009 Sep 01; 36(9):1565-8. PubMed ID: 19755835
    [Abstract] [Full Text] [Related]

  • 17. Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer.
    Lee SJ, Cho SH, Yoon JY, Hwang JE, Bae WK, Shim HJ, Chung IJ.
    Cancer Chemother Pharmacol; 2009 Dec 01; 65(1):159-66. PubMed ID: 19479256
    [Abstract] [Full Text] [Related]

  • 18. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial.
    Tsuburaya A, Yoshida K, Kobayashi M, Yoshino S, Takahashi M, Takiguchi N, Tanabe K, Takahashi N, Imamura H, Tatsumoto N, Hara A, Nishikawa K, Fukushima R, Nozaki I, Kojima H, Miyashita Y, Oba K, Buyse M, Morita S, Sakamoto J.
    Lancet Oncol; 2014 Jul 01; 15(8):886-93. PubMed ID: 24954805
    [Abstract] [Full Text] [Related]

  • 19. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group.
    Koizumi W, Kurihara M, Nakano S, Hasegawa K.
    Oncology; 2000 Apr 01; 58(3):191-7. PubMed ID: 10765119
    [Abstract] [Full Text] [Related]

  • 20. [Effect of Post-Gastrectomy Adjuvant S-1 Chemotherapy on Muscle Volume in Gastric Cancer Patients].
    Iwazawa T, Kawanishi K, Fujita J, Takata A, Hirota M, Imamura H, Ikeda A, Hokonohara K, Yoneyama C, Kameyama A, Shinke G, Oshima K, Tanida T, Hatano H, Noda T, Komori T, Morita S, Akagi K, Dono K.
    Gan To Kagaku Ryoho; 2015 Aug 01; 42(8):957-60. PubMed ID: 26321709
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.